Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Kyowa Kirin Co: Clinical Trials & FDA Approval Profile

Kyowa Kirin Co (Global / Institutional) sponsors 25 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 6 active protocols (3 recruiting now), 18 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.0%
Median Closed Enrollment vs National (145 pts)113 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Kyowa Kirin Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)25
Active Pipeline (Recruiting Now)6 (3)
Completed vs Stopped Early18 / 1 (4.0%)
Median Closed Actual Enrollment113 participants
Physical Hospital Site Disclosure99.2% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Kyowa Kirin Co
Hospital Research SiteLocationShared Protocols
Okayama University HospitalOkayama4
Hokkaido University HospitalSapporo, Hokkaido4
Osaka Metropolitan University HospitalOsaka3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Kyowa Kirin Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04533581Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)Phase IIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Kyowa Kirin Co Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI